# Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular Edema

> **NCT01823081** · PHASE3 · COMPLETED · sponsor: **Shahid Beheshti University of Medical Sciences** · enrollment: 74 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** Intravitreal injection of bevacizumab (Avastin)
- **DRUG:** Intravitreal injection of fasudil and bevacizumab (Avastin)

## Key facts

- **NCT ID:** NCT01823081
- **Lead sponsor:** Shahid Beheshti University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2013-06
- **Final completion:** 2015-12
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2017-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01823081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01823081, "Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01823081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*